Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Dow
Mallinckrodt
Johnson and Johnson
Boehringer Ingelheim
Merck
McKesson

Last Updated: November 12, 2019

DrugPatentWatch Database Preview

Details for Patent: 7,820,671

See Plans and Pricing

« Back to Dashboard

Summary for Patent: 7,820,671
Title:Peptidomimetic protease inhibitors
Abstract: The present invention relates to peptidomimetic compounds useful as protease inhibitors, particularly as serine protease inhibitors and more particularly as hepatitis C NS3 protease inhibitors; intermediates thereto; their preparation including novel steroselective processes to intermediates. The invention is also directed to pharmaceutical compositions and to methods for using the compounds for inhibiting HCV protease or treating a patient suffering from an HCV infection or physiological condition related to the infection. Also provided are pharmaceutical combinations comprising, in addition to one or more HCV serine protease inhibitors, one or more interferons exhibiting anti-HCV activity and/or one or more compounds having anti HCV activity and a pharmaceutically acceptable carrier, and methods for treating or preventing a HCV infection in a patient using the compositions. The present invention is also directed to a kit or pharmaceutical pack for treating or preventing HCV infection in a patient.
Inventor(s): Babine; Robert Edward (Carlsbad, CA), Chen; Shu Hui (Thousand Oaks, CA), Collado; Ivan (Madrid, ES), Garcia-Paredes; Cristina (Madrid, ES), Glass; John Irvin (Germantown, MD), Guo; Deqi (Carmel, IN), Jin; Ling (Indianapolis, IN), Lamar; Jason Eric (Indianapolis, IN), Parker, III; Raymond Samuel (Doylestown, PA), Snyder; Nancy June (Lizton, IN), Sun; Xicheng David (Broumfied, CO), Tebbe; Mark Joseph (Zionsville, IN), Victor; Frantz (Indianapolis, IN), Wang; Q. May (Indianapolis, IN), Yip; Yvonne Yee Mai (Indianapolis, IN), Perni; Robert B. (Marlborough, MA), Farmer; Luc (Foxborough, MA)
Assignee: Vertex Pharmaceuticals Incorporated (Cambridge, MA)
Application Number:10/344,112
Patent Claim Types:
see list of patent claims
Compound; Composition;

Drugs Protected by US Patent 7,820,671

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Vertex Pharms INCIVEK telaprevir TABLET;ORAL 201917-001 May 23, 2011 DISCN No No   Start Trial   Start Trial Y Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 7,820,671

PCT Information
PCT FiledAugust 31, 2001PCT Application Number:PCT/US01/26008
PCT Publication Date:March 07, 2002PCT Publication Number: WO02/18369

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
McKinsey
Medtronic
Mallinckrodt
Boehringer Ingelheim
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.